Telomir Pharmaceuticals, Inc. (TELO) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Telomir Pharmaceuticals, Inc., a Florida corporation listed on The Nasdaq Stock Market LLC under the symbol "TELO". The report covers an event occurring on March 30, 2026, and was signed by the Chief Executive Officer on March 31, 2026. The Company is designated as an emerging growth company.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a notification of a regulatory status update and does not contain financial statements or performance metrics.
Material Changes
The material change reported is the resolution of a listing compliance issue. On March 30, 2026, the Company received confirmation from Nasdaq Capital Markets that it is now in compliance with Nasdaq Listing Rule 5620(a) following the holding of its 2025 Annual Meeting of Shareholders. Nasdaq has determined the matter is now closed.
Guidance, Outlook, and Risks
The filing contains no management commentary regarding future guidance, outlook, or specific risks beyond the resolution of the listing compliance matter. No unusual items or contingencies are disclosed in this document.
Investor Verification Checklist
- Verify the Company's continued compliance with Nasdaq listing standards following the closure of the Rule 5620(a) matter.
- Confirm the date and outcomes of the 2025 Annual Meeting of Shareholders referenced in the compliance letter.
- Review the Company's most recent periodic reports (10-K or 10-Q) for financial data, as this 8-K does not contain financial metrics.